Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2018 | Lung cancer treatment: where are we now?

New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy increasingly redundant. Matti Aapro, MD, of the Clinique de Genolier, Genolier, Switzerland, spoke to us about this exciting new treatment landscape at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He discusses TKIs, immunotherapy, and the importance of continued adherence to guidelines and good scientific practice in the face of so many potential treatments.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.